Hamlet BioPharma has secured continued production of Alpha1-peptide with the Swiss public company Polypeptide Group. The new production, at a larger scale, will be essential for the clinical trial program in bladder cancer, currently advancing towards Phase III. Hamlet BioPharma announces an important milestone by advancing pharmaceutical manufacturing of the Alpha1 peptide with the Polypeptide Group, a leading CDMO company in peptide synthesis.

Through a cooperative effort with the Polypeptide Group's facilities in Strasbourg and Malmö over the years, Hamlet BioPharma has developed large-scale synthesis methods with Good Manufacturing Practice (GMP) quality. The recent agreement will secure supply of the Alpha1 peptide for use in the formulation of Hamlet BioPharmas lead drug candidate Alpha1H. The Alpha1H complex, which is produced from the synthetic alpha1 peptide, has shown excellent clinical efficacy and stability.